| 1 |
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
Kishore M. Gadde, David Blair Allison, Donna H. Ryan et al. · The Lancet
|
Apr 2011 |
1,062 |
| 2 |
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik Kumar Ray, Ulf Landmesser, Lawrence A. Leiter et al. · New England Journal of Medicine
Open access |
17 Mar 2017 |
1,000 |
| 3 |
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick Johan Raal, David G. Kallend, Kausik Kumar Ray et al. · New England Journal of Medicine
Open access |
18 Mar 2020 |
824 |
| 4 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison, Mustafa Rifaat Bashir, Cynthia D. Guy et al. · The Lancet
|
Nov 2019 |
794 |
| 5 |
Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
David Blair Allison, Kishore M. Gadde, William Timothy Garvey et al. · Obesity
Open access |
3 Nov 2011 |
725 |
| 6 |
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
William Timothy Garvey, Donna H. Ryan, Michelle Look et al. · American Journal of Clinical Nutrition
Open access |
8 Dec 2011 |
715 |
| 7 |
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al. · Hepatology
Open access |
17 Aug 2017 |
676 |
| 8 |
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein, Scott J. Mellis, George D. Yancopoulos et al. · New England Journal of Medicine
Open access |
22 Mar 2012 |
673 |
| 9 |
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Michael Walter Weiner, Paul S. S Aisen, Clifford R. Jack et al. · Alzheimer s & Dementia
Open access |
May 2010 |
617 |
| 10 |
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney, Michael J. Koren, Dean J. Kereiakes et al. · Journal of the American College of Cardiology
Open access |
28 Mar 2012 |
514 |
| 11 |
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth, James M. McKenney, Corinne Hanotin et al. · New England Journal of Medicine
Open access |
31 Oct 2012 |
470 |
| 12 |
Associations Between Screen-Based Media Use and Brain White Matter Integrity in Preschool-Aged Children
John Hutton, Jonathan A. Dudley, Tzipi Horowitz‐Kraus et al. · Archives of Pediatrics and Adolescent Medicine
Open access |
4 Nov 2019 |
468 |
| 13 |
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
Mason Wright Freeman, Yuan‐Di C. Halvorsen, William Marshall et al. · New England Journal of Medicine
Open access |
7 Nov 2022 |
384 |
| 14 |
Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
Manuel Haschke, Manfred Schuster, Marko Poglitsch et al. · Clinical Pharmacokinetics
|
16 May 2013 |
381 |
| 15 |
Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial
David Charles Hess, Lawrence R. Wechsler, Wayne M. Clark et al. · The Lancet Neurology
|
17 Mar 2017 |
377 |
| 16 |
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison, Peter Jerome Ruane, Bradley L. Freilich et al. · Nature Medicine
|
Jul 2021 |
363 |
| 17 |
Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)
Harold Edward Bays, Christie Mitchell Ballantyne, John J.P. Kastelein et al. · The American Journal of Cardiology
|
22 Jun 2011 |
356 |
| 18 |
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
Christie Mitchell Ballantyne, Harold Edward Bays, John J.P. Kastelein et al. · The American Journal of Cardiology
|
20 Jul 2012 |
344 |
| 19 |
OpenFold: retraining AlphaFold2 yields new insights into its learning mechanisms and capacity for generalization
Gustaf Ahdritz et al. · Nature Methods
Open access |
14 May 2024 |
331 |
| 20 |
Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes
Catherine C. Robertson et al. · Nature Genetics
|
14 Jun 2021 |
308 |
| 21 |
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels
Steven E. Nissen, Kathy Wolski, Craig Balog et al. · JAMA
Open access |
3 Apr 2022 |
300 |
| 22 |
De novo design of modular and tunable protein biosensors
Alfredo Quijano‐Rubio, Andy Hsien-Wei Yeh, Jooyoung Park et al. · Nature
Open access |
27 Jan 2021 |
277 |
| 23 |
Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: results from the population-based SEARCH for Diabetes in Youth study
Lynne E. Wagenknecht, Jean M. Lawrence, Scott P. Isom et al. · The Lancet Diabetes & Endocrinology
Open access |
28 Feb 2023 |
258 |
| 24 |
We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine
Kathryn M. Lemberg, James J. Vornov, Rana Rais et al. · Molecular Cancer Therapeutics
Open access |
Sep 2018 |
256 |
| 25 |
The efficacy of a brief app-based mindfulness intervention on psychosocial outcomes in healthy adults: A pilot randomised controlled trial
Louise Champion, Marcos Economides, Chris Chandler · PLoS ONE
Open access |
31 Dec 2018 |
246 |
| 26 |
Standardization of analysis sets for reporting results from ADNI MRI data
Bradley T. Wyman et al. · Alzheimer s & Dementia
Open access |
27 Oct 2012 |
240 |
| 27 |
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease
Clifford R. Jack et al. · Alzheimer s & Dementia
Open access |
Jul 2011 |
225 |
| 28 |
Machine learning for comprehensive forecasting of Alzheimer’s Disease progression
Charles K. Fisher et al. · Scientific Reports
Open access |
20 Sep 2019 |
223 |
| 29 |
Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Matthew C. Riddle, Guillermo E. Umpierrez, ANDRES G. DIGENIO et al. · Diabetes Care
Open access |
26 Oct 2011 |
219 |
| 30 |
Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
William Timothy Garvey, Donna H. Ryan, Robert R. Henry et al. · Diabetes Care
Open access |
9 Oct 2013 |
215 |
| 31 |
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors
Aditya Bagrodia et al. · Journal of Clinical Oncology
Open access |
20 Sep 2016 |
206 |
| 32 |
Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH
Stephen A. Harrison, Mustafa Rifaat Bashir, Sam E. Moussa et al. · Hepatology Communications
Open access |
4 Jan 2021 |
195 |
| 33 |
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
Stephen James Nicholls, Marc Ditmarsch, John J.P. Kastelein et al. · Nature Medicine
Open access |
Aug 2022 |
174 |
| 34 |
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds
Sotirios Tsimikas, Santica M. Marcovina · Journal of the American College of Cardiology
Open access |
Aug 2022 |
150 |
| 35 |
Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus
Deepak L. Bhatt, Tilo Großer, Jing-fei Dong et al. · Journal of the American College of Cardiology
Open access |
11 Jan 2017 |
149 |
| 36 |
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance
Paul Daniel Thompson, Diane Elaine MacDougall, Roger S. Newton et al. · Journal of clinical lipidology
Open access |
6 Jan 2016 |
147 |
| 37 |
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel
Paul Alfred Gurbel, Kevin P. Bliden, Douglas K. Logan et al. · Journal of the American College of Cardiology
Open access |
17 Apr 2013 |
139 |
| 38 |
Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-κB Signaling Pathways
Dalia Haydar, Theodore James Cory, Susan E. Birket et al. · The Journal of Immunology
Open access |
Jul 2019 |
135 |
| 39 |
Multiplatform molecular test performance in indeterminate thyroid nodules
Mark Armin Lupo, Ann E. Walts, John Woody Sistrunk et al. · Diagnostic Cytopathology
Open access |
7 Aug 2020 |
117 |
| 40 |
Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease
Matthew J. Price, James S. Walder, Brian Baker et al. · Journal of the American College of Cardiology
Open access |
Jun 2012 |
117 |
| 41 |
Lp(a): When and how to measure it
Jaimini Cegla, Michael W. France, Santica M. Marcovina et al. · Annals of Clinical Biochemistry International Journal of Laboratory Medicine
Open access |
12 Oct 2020 |
114 |
| 42 |
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
Stephen A. Harrison, Peter Jerome Ruane, Bradley L. Freilich et al. · JHEP Reports
Open access |
23 Aug 2022 |
107 |
| 43 |
A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer
Miklos Pless, C. Droege, Roger von Moos et al. · Lung Cancer
|
23 Jul 2013 |
107 |
| 44 |
A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)
Kevin Carl Maki, David G. Orloff, Stephen James Nicholls et al. · Clinical Therapeutics
|
30 Aug 2013 |
105 |
| 45 |
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Stephen James Nicholls et al. · New England Journal of Medicine
Open access |
7 May 2025 |
99 |
| 46 |
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
Stephen A. Harrison, Juan P. Frías, Kathryn Jean Lucas et al. · Clinical Gastroenterology and Hepatology
Open access |
4 Mar 2024 |
99 |
| 47 |
Recent advances in electrogenerated chemiluminescence biosensing methods for pharmaceuticals
Yu Zhang, Rui Zhang, Xiaolin Yang et al. · Journal of Pharmaceutical Analysis
Open access |
22 Nov 2018 |
97 |
| 48 |
Early human impacts and ecosystem reorganization in southern-central Africa
Jessica C. Thompson et al. · Science Advances
Open access |
5 May 2021 |
91 |
| 49 |
Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
Evan A. Stein, Gary D. Swergold · Current Atherosclerosis Reports
|
31 Jan 2013 |
85 |
| 50 |
Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
Jerry R. Colca, James T. VanderLugt, Wade J. Adams et al. · Clinical Pharmacology & Therapeutics
Open access |
18 Jan 2013 |
84 |